Summary
- Profile Type
- Business Offer
- POD Reference
- BOSG20240607007
- Term of Validity
- 7 June 2024 - 7 June 2025
- Company's Country
- Singapore
- Type of partnership
- Commercial agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- Incorporated in 2021, a Singapore-based ISO13485-certified medical technology company that provides digital, AI-powered diagnostic ophthalmology solutions to enable self-administered community-based vision screening for early detection and treatment of vision impairment as well as non-invasive diagnostic solutions.
- Full Description
-
Jointly developed by the Department of Ophthalmology at the National University Hospital, Centre for Innovation and Precision Eye Health at the Yong Loo Lin School of Medicine, National University of Singapore (“NUS Medicine”) and DLL, our Automated Visual Acuity Testing Device (“AVAT”) addresses the increasing demand to decentralise the existing care model of conducting eye screening and monitoring of eye diseases. By incorporating automation and digitalisation, AVAT has allowed for more efficient vision testing workflow with minimal costs and manpower resources.
Leveraging on the proprietary optics and intelligent software programming, AVAT recapitulates the standard 6-meter visual acuity test within a tabletop footprint and allows for patients to perform the assessment without the need for trained staff.
The system provides Snellen’s Tumbling E test formats in multiple languages. It also has a pinhole test feature to assess if the “poor vision” is the result of refractive error and if so, it will guide the patients on the subsequent steps to be taken. Results can be easily integrated into electronic medical records, thereby cutting down on human error during data input.
By reducing the need for trained operators, AVAT not only addresses the manpower shortages in the healthcare systems, but also ensures a consistent level of test quality and eliminates human error. Patients have indicated a preference for the AVAT testing format, as it has the potential to significantly reduce wait times and remove the major bottleneck in the clinic workflow. - Advantages and Innovations
-
- Afocal lens technology and adaptive computer algorithm provide clinical-grade accuracy, validated at the National University Hospital (Singapore).
- Small physical footprint – 6 times reduction in size means more VA testing can be performed without increasing floorspace or manpower.
- Easy, intuitive test workflow for self-testing with minimal or no supervision thereby eliminates the need for skilled optometrist to administer test.
- VA testing can be performed at any time in hospitals and communities (schools, GPs) to offer comprehensive, convenient screening.
- Results can be seamlessly integrated in existing electronic medical records or secured cloud storage for easy retrieval and removes human error. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
Partner Sought
- Expected Role of a Partner
- Distributor
- Type and Size of Partner
- Big company
- SME 50 - 249
- Other
- SME 11-49
- SME <=10
- Type of partnership
- Commercial agreement
Dissemination
- Market keywords
- 09004008 - Other manufacturing (not elsewhere classified)
- Targeted countries
- All countries